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Abstract: Peripartum cardiomyopathy is a relatively rare disease, which can have devasting consequences and should be 
promptly identified and correctly treated. Overall prognosis is good in majority of the cases, although some patients may 
progress to irreversible heart failure. Early diagnosis is important and effective treatment reduces mortality rates and 
increases the chance of complete recovery of ventricular systolic function.  
We report of an interesting case with a favourable outcome and discuss about the clinical presentation, therapy and 
outcome of this condition. 
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INTRODUCTION 
  Although the diagnostic criteria for peripartum cardio-
myopathy (PCM) were established many decades ago, [1] its 
causes still remain unclear. The principal hypotheses with 
regards to the pathogenesis of this cardiomyopathy include 
an autoimmune response, an abnormal reaction to 
physiologic hormones or a viral aetiology [2-5]. PCM is a 
syndrome with symptoms of heart failure and signs of left 
ventricular systolic dysfunction, which manifest between the 
last month of pregnancy and the first 5 months postpartum 
[6]. Its incidence varies from 0.2% to 3% live births [6-8] 
and from region to region worldwide. The prognosis is 
generally good in the majority of cases although some 
patients progress to irreversible heart failure, heart 
transplantation or death [8, 9]. The diagnosis of PCM is 
made in the presence of symptoms and signs of heart failure 
strictly associated with partum and in the absence of other 
possible causes of dilated cardiomyopathy. The presence of 
ventricular systolic dysfunction is essential for diagnosis. 
Some echocardiographic parameters like an ejection fraction 
(EF) of less than 45% and an end-diastolic dimension index 
of greater than 2.7 cm/m
2 have been proposed to better 
classify the dysfunction [10]. 
CASE REPORT 
  A 34 years old lady was referred to our cardiological 
intensive care unit from a peripheral hospital. She had been 
admitted there for cough and dyspnoea which developed on 
the 15
th day after the delivery of her third child. A month 
prior to delivery she started feeling weak with dyspnoea and 
hypertension but declined treatment for hypertension and the 
dyspnoea symptoms were not investigated further. The chest 
x-ray on admission showed acute pulmonary oedema with  
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bilateral pleural effusion and she was commenced on 
diuretics, ACE-inhibitors and antibiotics. Since the patient 
did not show any clinical improvement over the next 2 days, 
she was transferred to our intensive ward. On admission she 
was hypotensive (90 mmHg systolic blood pressure), with 
sinus tachycardia at 120 bpm with a gallop and diffuse rales 
on lung auscultation. ECG revealed diffuse T wave 
inversion. Echocardiography showed the presence of a 
severely impaired left ventricular systolic function with EF 
of 30%, fractional shortening of 11% along with severe 
mitral regurgitation and moderate tricuspidal regurgitation. 
Right and left ventricles appeared severely enlarged and 
diffusely hypokinetic. End-diastolic volume of the left 
ventricle was 118 ml/m
2 and end-diastolic dimension 6.5 cm 
with an end-diastolic dimension index of 3.96 cm/m
2. Bi-
atrial enlargement was also noted. White cell count was 
6700/cubic mm, Hb 9.8 g/dl, C reactive protein 0.21 mg/dl 
(normal value < 0.5), BNP 689 pg/ml (normal value < 100 
pg/ml). The thyroid hormone profile was normal. Serological 
tests for the usual viral agents responsible for myocarditis 
were negative.  
  Antibiotic therapy was discontinued while the diuretics 
were continued. To correct the hypotension and improve 
perfusion, saline was infused gently (1.5 l/24 hours) while 
closely monitoring for any further evidence of fluid 
overload. ACE-inhibitors were cautiously initiated since the 
systolic blood pressure was low at 85-90 mmHg. Beta-
blocker was started on the second day of admission at a low 
dose (bisoprolol 1.25 mg). The patient was also commenced 
on enoxaparin for thrombo-prophylaxis, because of the 
enlarged LV with significant dysfunction.  
  Chest x-ray on day 15 showed resolution of the pulmo-
nary oedema and pleural effusions. Follow up echocardio-
graphy showed improvement of mitral insufficiency, which 
became mild by day 30 along with normalisation of 
dimension and function of right ventricle and disappearance 
of tricuspid insufficiency. While the volumes of the left 
ventricle decreased, EF remained severely depressed (29% at Peripartum Cardiomyopathy  Current Cardiology Reviews, 2009, Vol. 5, No. 4    269 
discharge). BNP levels trended down to 614 pg/ml on day 15 
after having risen to a peak level of 1111 pg/ml on day 5. 
The patient was discharged from the hospital on day 17 on 
furosemide 25 mg/day, lisinopril 20 mg/day, bisoprolol 2.5 
mg/day, enoxaparin 8000 UI/day. Iron supplementation was 
also recommended. 
  During the follow up there was a continuous improve-
ment of left ventricle dimensions and function and a decrease 
of BNP levels. Left ventricle EF increased to 40% by day 30 
and BNP decreased to less than 100 pg/ml on day 45. The 
trend of left ventricle volumes and function is shown in Fig. 
(1) and that of BNP levels in Fig. (2). 
DISCUSSION 
  This case report highlights the diagnostic and therapeutic 
dilemma that physicians face when encountering patients 
with the rare, but interesting condition of peripartum cardio-
myopathy which warrants prompt identification and 
treatment. 
CLINICAL FEATURES 
  PCM usually presents with classical symptoms and sign 
of systolic heart failure with ventricular enlargement and 
dysfunction seen on echocardiography. Often there is 
significant mitral and tricuspid regurgitation [11]. Unusual 
presentations include thromboembolism or hepatic failure 
secondary to heart failure. The development of heart failure 
and the usual time of diagnosis are during the post-partum 
period in more than 90% of the cases [12]. PCM can occur at 
any age with a higher incidence in women older than 30 
years [1, 9]. 
  The diagnosis of PCM is challenging because most 
women in the last months of a normal pregnancy or soon 
after the delivery experience dyspnoea, fatigue and pedal 
oedema. Symptoms and signs which should raise the 
suspicion of heart failure and could help the clinicians in the 
diagnosis, are the presence of paroxysmal nocturnal dysp-
noea, nocturnal cough, new regurgitant murmurs, pulmonary 
crackles, jugular venous distention and hepatomegaly [13]. 
PATHOGENESIS 
  The aetiology and pathogenesis seems to be multi-
factorial and poorly understood with the available literature 
rather conflicting.  
  Gestational hypertension, tocolytic therapy and twin 



















Fig. (1). Trend of left ventricle volumes, function and heart rate. EDVi: end-diastolic volume index; ESVi: end-systolic volume index; EF: 
left ventricular ejection fraction; HR: heart rate. 270    Current Cardiology Reviews, 2009, Vol. 5, No. 4  Cemin et al. 
because they were commonly associated with PCM [9]. 
These observations were not confirmed from other authors 
[14] who did not find any association between PCM and 
history of hypertension during pregnancy or use of tocolytc 
agents. 
  The association between PCM and twin pregnancy could 
support the theory of autoimmunity as a possible mechanism. 
This could depend on an excessive traffic of haematopoietic 
lineage cells from the foetus to the mother as manifest in 
twin pregnancy [15]. Usually the lower concentrations of 
these foreign proteins could contribute to tolerance of the 
foetus while increased levels could theoretically lead to the 
initiation of autoimmune disease [11]. The weak immuno-
genicity of the paternal haplotype of the chimeric cells or the 
naturally immunosuppressive state of the mother or both 
could avoid rejection of foetal cells during pregnancy. 
Following postpartum, the recovery of immune competence 
could trigger a pathologic autoimmune response against 
cardiac cells where haematopoietic cells have taken up 
residence during pregnancy and therefore myocardial cells 
are recognised as nonself [6]. 
  Multiparity could be another risk factor for the develop-
ment of PCM [13] and again, this observation has not been 
confirmed from other authors. In fact more than 50% of the 
patients are at their first or second pregnancy [9].  
  Molecular markers of an inflammatory process are found 
in most of the patients. 90% of the patients show high levels 
of plasma C-reactive protein that correlated positively with 
LV end-diastolic and end-systolic dimensions and inversely 
with LV ejection fractions [14]. This could indicate the 
chronic inflammatory state at baseline, which is higher in 
more unstable patients. The presence of a low-grade chronic 
inflammatory process could be due to the release of endo-
toxins and subsequent release of pro-inflammatory cytokines 
[16]. 
  Interestingly, the possibility of developing PCM in a 
surrogate mother whose embryo was received from the 





















Fig. (2). Trend of BNP levels over time. Peripartum Cardiomyopathy  Current Cardiology Reviews, 2009, Vol. 5, No. 4    271 
with PCM following the delivery of her first child [17], 
points out the possible role of the presence of a transmissible 
agent, either infectious or non-infectious as well as genetic 
susceptibility. A hereditary predisposition is also suggested 
by familial reports of PCM [17] and strong consideration 
should be given to screening family members because PCM 
may be the forme fruste of a genetic predisposition to 
cardiomyopathy [6]. 
PROGNOSIS 
  Overall prognosis of PCM is good in majority of the 
cases, although some patients may progress to irreversible 
heart failure. Progression of the condition requiring heart 
transplantation is described in 4% and death in 9% at a two 
years follow up [9]. Other studies showed a much higher 
mortality rate such as 15% or 32% at 6 months [14,18]. 
Patients who eventually die tend to have worse NYHA 
functional class, LVEF and larger LV dimensions at diag-
nosis [14]. There seems to be an initial high-risk period with 
25-50% of the women dying within the first 3 months 
postpartum [19]. 
  Sudden cardiac death has been reported to account for up 
to 50% of the mortality [20] and therefore attention should 
be paid to identify those patients who are likely to expe-
rience a late recovery of systolic function from those who 
should be considered for implantation of a cardioverter-
defibrillator. Mortality rates have decreased over the past 10 
years due to advances in medical therapy for heart failure 
and use of implantable defibrillators [21]. Normalisation of 
left ventricular systolic function occurs in 23% and in 54% 
of the patients respectively at six months [14] and at two 
years and is more likely if EF at diagnosis is more than 30% 
[9]. Higher left ventricular end diastolic dimension and lower 
fractional shortening at diagnosis seems to be associated to a 
worse prognosis. A fractional shortening of less than 20% 
and a left ventricular end diastolic dimension of 6 cm or 
greater was associated with a more than 3-fold higher risk 
for persistent left ventricular dysfunction [22]. 75% of the 
patients, who recover, have an EF of more than 45% at two 
months after diagnosis [23]. 
  Complete recovery of systolic function occurs usually in 
the first 6 months after delivery [9] although the recovery 
phase need not be limited to the first 12 months. Continuing 
improvement was observed in the second and third year after 
diagnosis  [7]. Persistence of the disease after 6 months 
portends worse survival [24]. 
  To get an assessment of prognosis at the time of diag-
nosis, a dobutamine stress echocardiography study could be 
performed in non-critically ill patients. Inotropic contractile 
reserve accurately correlated with subsequent recovery of 
left ventricular function and usually associated with a benign 
prognosis  [19]. MRI could be a useful alternative to 
dobutamine stress echocardiography in predicting outcome. 
Delayed gadolinium enhancement is more likely to be 
present in patients less responding to conventional therapy 
but could resolve over time in the recovering patients [25].  
  Even if left ventricular function recovers completely, 
exercise tolerance may remain abnormal and this could be 
more objectively assessed by an abnormal response to 
dobutamine stress echocardiography.  
THERAPY 
  Management involves conventional therapy for heart 
failure with diuretics, ACE-inhibitors, beta-blockers and 
aldosterone antagonists. Angiotensin-receptor blockers 
should be added in case of ACE-inhibitors intolerance. 
Anticoagulant therapy should be considered in view of the 
low left ventricular EF, which predisposes to thrombus 
formation, especially in the peripartum period when a 
hypercoagulable state exists. In patients not improving on 
conventional therapy or in patients with critical hemo-
dynamic state with cardiogenic shock, hemodynamic support 
with pressors should be considered. There have been some 
reports about the use of levosimendan [26] in non-responsive 
patients. 
  Non-responsive patients should be considered for heart 
transplantation even if there are some reports about effective 
use of extracorporeal membrane oxygenation [27], intra-
aortic balloon pump or mechanical assist devices. 
  Among patients who eventually recover, the withdrawal 
of heart failure medications was not associated with decom-
pensation over a follow-up of 29 months [23]. The duration 
of heart failure treatment is determined by the patient's heart 
performance at rest and with exertion. Patients with normal 
EF at rest and during dobutamine could taper off medical 
therapy in 6-12 months; patients with normal EF at rest and 
abnormal EF during dobutamine should be treated for longer 
period with ACE-inhibitors and betablockers [28]. Patients 
who continue to have a depressed ventricular function at rest 
have a poorer prognosis and should receive medical therapy 
indefinitely. In any case, it seems reasonable to continue at 
least for a year with ACE-inibitors and betablockers even in 
case of complete recovery. 
  It is important to note that the use of ACE-inhibitors 
should be limited to after delivery since they have terato-
genic effects. Other drugs like immunosoppressive drugs are 
still under evaluation. 
SUBSEQUENT PREGNANCIES 
  A subsequent pregnancy carries a high risk of relapse, 
significant decrease of left ventricular function and mor-
tality. Mortality rate is described to be approximately 55% 
during subsequent pregnancy [29] even though it seems 
associated more with patients who entered the subsequent 
pregnancy with abnormal systolic function i.e. without 
making a complete recovery [30]. Complete recovery from a 
relapse is very rare. There is no consensus regarding recom-
mendations for future pregnancy after PCM but patients 
whose left ventricular size or function does not return to 
normal should be counselled strongly to avoid subsequent 
pregnancy [6]. 
CONCLUSION 
  PCM is a relatively rare disease, which can have 
devasting consequences and should be promptly identified 
and correctly treated. Early diagnosis is important and 272    Current Cardiology Reviews, 2009, Vol. 5, No. 4  Cemin et al. 
therefore women who develop symptoms of heart failure 
during pregnancy or shortly after should be investigated for 
this condition. Effective treatment reduces mortality rates 
and increases the chance of complete recovery of ventricular 
systolic function. 
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